Experimental study of [68Ga]Ga-HER2-RGD, a dual-target molecular probe, for breast cancer PET/CT imaging Authors: Xiujuan Zhao, Meng Dai, Tianyue Li, Nuo Li, Xiaolin Chen, Bo Dong, Yingxiao Guo, Mengyue Wei, Xinming Zhao, Jingmian Zhang Published: 2026 ABSTRACT BackgroundRadiolabeled heterodimeric peptides have emerged as a highly promising targeting strategy for PET imaging due to their superior binding properties. The Human epidermal growth factor receptor 2 (HER2)- and Arg-Gly-Asp (RGD)-targeting moieties bind to HER2 and integrin αvβ3, respectively, receptors that are both overexpressed in many different types of tumors. This study focuses on the synthesis and evaluation of the heterodimeric radioligand [68Ga]Ga-DOTA-HER2-RGD for PET imaging of the breast cancers-bearing mouse models that overexpress HER2 and/or integrin αvβ3.ResultsThe heterodimeric radiopeptide was successfully synthesized and radiolabeled with 68Ga, achieving a radiochemical purity of > 95%. The receptor-binding properties and tumor-targeting efficacy were evaluated in vitro and in vivo using three breast cancer cell lines—MDA-MB-435 S (high HER2, high αvβ3), MDA-MB-231 (high HER2, low αvβ3), and MCF-7 (low HER2, low αvβ3)—and their respective xenograft models. Flow cytometry verified the cell-surface expression profiles of HER2 and integrin αvβ3 in all three cell types. In vitro cell studies showed that the MDA-MB-435 S cell line exhibited the highest uptake of [68Ga]Ga-HER2-RGD, followed by MDA-MB-231 and MCF-7. High specificity was demonstrated in blocking studies using excess unlabeled HER2-RGD. Competitive binding assays revealed that [68Ga]Ga-HER2-RGD exhibited high binding affinity, with an IC50 value of 12.9 nM. Micro-PET/CT imaging revealed a significant accumulation of [68Ga]Ga-HER2-RGD in MDA-MB-435 S xenografts, with no or very low uptake in nontarget organs and tissues. Consistent with the in vitro findings, the tumor-to-nontumor ratios across the three xenograft models followed the order: MDA-MB-435 S > MDA-MB-231 > MCF-7. A significant decrease in [68Ga]Ga-HER2-RGD uptake in the MDA-MB-435 S xenografts was observed after the administration of blocking amount of HER2-RGD.Conclusion[68Ga]Ga-HER2-RGD demonstrates specific dual-receptor-targeting properties towards HER2 and integrin αvβ3, as evidenced by in vitro and in vivo studies. This radiopeptide shows promise as a novel PET agent for the noninvasive visualization of HER2 and/or integrin αvβ3 expression in breast cancer, and is capable of semi-quantitatively evaluating the expression levels of HER2 and/or integrin αvβ3 to a certain extent. Background Human epidermal growth factor receptor 2 (HER2) overexpression correlates with aggressive tumor biology, increased metastatic potential, therapeutic resistance, and reduced overall survival [1]. HER2-targeted antibody-drug conjugates (ADCs) have shown impressive results for breast cancer throughout multiple studies [2–3]. Molecular imaging techniques, exemplified by PET/CT, offer significant advantages in the personalized diagnosis and treatment of malignant neoplasms. To date, a variety of HER2-targeting molecular probes have been established for PET/CT imaging, include [89Zr]Zr-trastuzumab, [89Zr]Zr-pertuzumab and [68Ga]Ga-ABY−025 [4–5]. Radiotheranostic approaches that employ radiolabeled HER2-targeting agents, like [177Lu]Lu-DOTA-trastuzumab, enable the selective targeting of HER2-positive tumors [6]. Nevertheless, HER2-negative breast cancer represents the vast majority (70–85%) of breast cancer cases, mainly stratified into HR+/HER2- and triple-negative breast cancer (TNBC) [7]. TNBC, in particular, poses a formidable clinical challenge due to its aggressive phenotype, high propensity for relapse, and the paucity of definitive molecular targets, which collectively constrain available therapeutic strategies [8]. As a cell adhesion receptor, integrin αvβ3 represents one of the most critical protein biomarkers in the field of cancer imaging and therapy [9]. While absent in quiescent endothelial cells, it is notably upregulated on activated endothelial cells during angiogenesis and is overexpressed on tumor cells in a variety of cancers. Notably, integrin αvβ3 is widely expressed in breast cancer and metastatic lesions, particularly in bone metastases [10]. Its expression level correlates positively with tumor aggressiveness, establishing it as a pivotal target in precision oncology. Synthetic peptides based on the Arg-Gly-Asp (RGD) sequence have been identified as effective modulators of cellular adhesion, exhibiting high affinity and specificity for integrin αvβ3. Radiolabeled cyclic RGD peptides have shown promising results in preclinical and clinical settings for imaging integrin αvβ3-positive cancers. A pioneering first-in-human Phase I trial conducted by Kenny et al. in 2008 explored RGD PET in breast cancer patients, establishing a foundation for future agent development [11]. Notably, [18F]FPPRGD2 PET demonstrated superior sensitivity and specificity in detecting breast lesions and metastatic lesions compared to [18F]FDG PET/CT, with rates of 95.7% vs. 87.0%, and 100% vs. 57.1%, respectively [12]. However, integrins are upregulated in non-neoplastic pathological conditions, such as wound healing and inflammation, leading to false-positive results [13]. Heterodimerization, facilitated by the binding of optimal tumor-specific biomarker pairs, represents a promising targeting strategy for PET radiotracers. In particular, compared to monomeric approaches, heterodimeric strategies broaden the detection spectrum, thereby enhancing diagnostic sensitivity [14–16]. [68Ga]Ga-BBN-RGD PET/CT detected primary tumors in 81.8% (9/11) of breast cancer patients, outperforming [68Ga]Ga-BBN PET/CT (63.6%, 7/11) with significantly higher SUV (P < 0.05) [14]. Kwon LY et al. [15] utilized breast cancer cell lines and xenograft models characterized by diverse HER2 and EGFR levels. Their findings revealed that the bispecific agent [64Cu]Cu-trastuzumab Fab-EGF exhibited significantly higher tumor accumulation than its monospecific tracers, [64Cu]Cu-trastuzumab Fab and [64Cu]Cu-EGF. Thus, HER2 and integrin αvβ3 are potential targets for radionuclide imaging and therapy. Co-targeting them could enhance tumor specificity and extend coverage to HER2-negative tumors. To date, there have been no reports on dual-target PET probes simultaneously targeting HER2 and integrin αvβ3. In this study, we aimed to develop a novel HER2 and integrin αvβ3 dual-targeting heterodimer, and facilitate its clinical translation. The RGD dimer enhances multivalent binding due to its low affinity, whereas the HER2 moiety, with its high affinity, requires no such enhancement. A monomeric HER2 also prevents receptor crosslinking and helps control the probe’s size for better tumor penetration. The heterodimer DOTA-(3PEG4)-HER2-E[cyclo(RGDfk)]2 was synthesized, radiolabeled with 68Ga, and evaluated in preclinical study. Materials and methods General All chemicals from Thermo Fisher Scientific were utilized as received, without additional purification, except where otherwise stated. The breast carcinoma cell lines were purchased from the Cell Bank of the Chinese Academy of Sciences (Beijing, China). [68Ga]GaCl3 was eluted from a 68Ge/68Ga generator (iThemba LABORATORIES, South Africa). Radioactivity was measured using a HA4300 Dose Calibrator (Medscan, China) and a γ-counter (CAPRAC-t, CAPINTEC, USA). Gradient RP-HPLC was applied to measure radiochemical purity using a Microsorb C18 column (model 305, 4.6 × 250 mm; Alltech Associates, Inc., USA) connected to radiodetector and NaI (Tl) radioactivity detectors. Micro-PET/CT imaging was conducted using a micro-PET/SPECT/CT scanner (NOVEL MEDICAL Equipment Ltd., China). Radiochemistry DOTA-HER2-RGD was custom manufactured by Kaixin Biotechnology Co., Ltd. (Xi’an, China) (Fig. 1A). The radioactive labeling was conducted manually in a hot cell immediately before administration. In short, a [68Ga]GaCl3 solution was obtained by eluting from a 68Ge/68Ga generator with 6 mL of 0.6 M HCl. This eluate (1.5 mL, 370–555 MBq) was combined with 1.7 mL of 1 M NaOAc buffer (pH 8.23) and 200 µL (22.68 nmol) of HER2-RGD solution (final pH 4.5). Subsequently, the reaction mixture was heated at 95 °C for 15 min. Radiochemical purity was analyzed via RP-HPLC. The column was eluted with a gradient of 5% − 95% solution A (0.1% TFA in acetonitrile) and 95% − 5% solution B (0.1% TFA in water) in 30 min at a flow rate of 1 mL/min with detection at 254 nm. Fig. 1(A) Chemical structure of [68Ga]Ga-HER2-RGD. Color coding: αvβ3-targeting peptide (red), PEG4 linker (green), HER2-targeting peptide (blue), and the DOTA chelator (black). (B) Analytical HPLC chromatogram of [68Ga]Ga-HER2-RGD showing a retention time of 17.06 min and a radiochemical purity > 95%. The relative intensity of radioactivity signals was expressed in millivolts (mV) (A) Chemical structure of [68Ga]Ga-HER2-RGD. Color coding: αvβ3-targeting peptide (red), PEG4 linker (green), HER2-targeting peptide (blue), and the DOTA chelator (black). (B) Analytical HPLC chromatogram of [68Ga]Ga-HER2-RGD showing a retention time of 17.06 min and a radiochemical purity > 95%. The relative intensity of radioactivity signals was expressed in millivolts (mV) Cell culture Three human breast carcinoma cell lines were utilized: MDA-MB-435 S (expressing high levels of HER2 and integrin αvβ3), MDA-MB-231 (high HER2, low integrin αvβ3), and MCF-7 (low HER2 and integrin αvβ3). These cells were maintained in Roswell Park Memorial Institute 1640 (RPMI 1640) medium containing 10% fetal bovine serum (FBS) and incubated at 37 °C in a humidified environment with 5% CO2. Cell growth was tracked via phase-contrast microscopy. When the cell density reached 90% confluence, cells were detached using 0.25% trypsin-0.02% EDTA (Invitrogen). Flow cytometry Flow cytometry was employed to quantify the surface expression of HER2 and integrin αvβ3 on MDA-MB-435 S, MDA-MB-231 and MCF-7 cells, as indicated by mean fluorescence intensity. The cells were harvested, resuspended in cold 1× Phosphate-buffered solution (PBS) (1 × 107 cells/mL), and incubated with antibodies for 30 min at 4 °C in the dark. Following two washes with 1×PBS, the samples were analyzed using a flow cytometer (Beckman Coulter, Inc.) and Kaluza analysis software (Kaluza Analysis). FITC-conjugated anti-HER2 antibody (clone AY13, BioLegend) was used for HER2 detection, and PE-conjugated anti-integrin αvβ3 antibody (clone BV3, Abcam) was used for integrin αvβ3 detection. Cellular uptake, blocking and retention studies MDA-MB-435 S, MDA-MB-231, and MCF-7 cells were plated in 6-well plates at a density of 6 × 10⁵ cells per well 24 h before the experiment. On the day of the test, the cells were rinsed twice with 0.5 mL of PBS and then incubated with 500 µL of growth medium. For the cellular uptake analysis, 37 kBq of [68Ga]Ga-HER2-RGD was added to each well. The plates were then incubated at 37 °C in an atmosphere containing 5% CO₂ for 30, 60, 90, and 120 min. In the blocking experiment, 10 µg of unlabeled compound was co-administered with 37 kBq of [68Ga]Ga-HER2-RGD, and the mixture was incubated for 90 min. After the incubation, the culture medium was aspirated. The cells were rinsed twice with 500 µL of PBS, and the rinse solutions were combined with the collected medium. Subsequently, the cells were lysed, and the wells were washed twice with 500 µL of PBS; these washes were pooled with the lysate. Finally, the radioactivity in both the cell lysates and supernatants was quantified using a γ-counter. To evaluate the cellular retention, confluent cells in 6-well plates were treated with 37 kBq of diluted [68Ga]Ga-HER2-RGD. The plates were maintained until peak binding was achieved. Subsequently, the medium was aspirated promptly, and the cells were rinsed twice with PBS. After replenishing with 2 mL of fresh medium, the cells were placed back into the incubator. At intervals of 30, 60, 90, and 120 min, both the supernatant and cells were collected to quantify radioactivity and determine the cellular retention rate. Each time point was assessed in six replicates. Competitive binding assays Competitive binding assays on MDA-MB-435 S cells (high HER2 and integrin αvβ3) were performed to evaluate the binding affinity of [68Ga]Ga-HER2-RGD. Cells were seeded in 48-well plates (5 × 104 cells/well) and incubated for 24 h. The medium was replaced with serum-free medium, and the probe (0.1µCi/µL) was added. Unlabeled HER2-RGD (10⁻⁵ to 10⁻¹¹ M) was added to compete for binding. After 60 min incubation and PBS washing, cells were trypsinized, collected, and their radioactivity was measured. The IC50 was determined by curve fitting with GraphPad Prism 9.5.0. Animal xenograft model All animal procedures were performed in compliance with the Principles approved by the Laboratory Animal Welfare and Ethics Committee of the Fourth Hospital of Hebei Medical University (Approval No. IACUC-4th Hos Hebmu-2023091). To establish breast cancer xenografts, female athymic nude mice received a subcutaneous injection of 5 × 106 human MDA-MB-435 S, MDA-MB-231 or MCF-7 cells into the right shoulder. Tumor growth was tracked using vernier calipers. Approximately 3 weeks after inoculation, mice bearing tumors with volumes of 200–250 mm3 were selected for imaging experiments. Molecular imaging and biodistribution Mice bearing MDA-MB-435 S, MDA-MB-231 and MCF-7 tumor xenografts underwent micro-PET/CT imaging under 2% isoflurane anesthesia (n = 3) following the tail vein administration of 7.4 MBq of [68Ga]Ga-HER2-RGD. Whole-body scans were conducted at 30, 60, 90, and 120 min post-injection. The computed tomography (CT) imaging was performed using settings of 80 kV, 0.5 mA, 2000 ms/frame, and 360 frames, with image reconstruction conducted via a 512 × 512 matrix and 0.18 mm slice thickness. Positron emission tomography (PET) scans were obtained using a 140 × 140 matrix over a 10-minute acquisition period. The animals remained conscious between scans. To evaluate the in vivo targeting specificity, a blocking experiment was performed. 200 µg of unlabeled HER2-RGD was co-injected with the corresponding [68Ga]Ga-HER2-RGD for mice bearing MDA-MB-435 S tumors (n = 3 per group). Following image reconstruction, the tumor-to-non-tumor (T/NT) ratio was calculated using NMSoft-AIWS software (v1.9; NovelMedical, Beijing, China) by delineating regions of interests (ROIs) for the tumor and the contralateral equivalent region at each time point. The uptake of [68Ga]Ga-HER2-RGD in major organs (heart, liver, kidney, lung, intestines, brain, bone, and muscle) and tumor was analyzed. ROIs were manually delineated to cover the entire organs and tissues on micro-PET/CT images using PMOD software (v4.201, PMOD Technologies LLC, Switzerland) at each time point. ROIs were contoured as follows: CT images were magnified to enhance the visibility of organs and tissues, and PET images were magnified accordingly. For all structures, contours were manually outlined slice-by-slice on axial PET images. Radioactivity in bone and muscle was measured in the tumor-free limbs. The intestinal ROI was defined as the jejunoileum. The results are presented as the percentage of the injected dose per gram of tissue (% ID/g). Statistical analysis Prism (version 10.0; GraphPad Software Inc.) and SPSS Statistics (version 26.0; IBM Corp.) were utilized for all data processing. Data were expressed as mean ± standard deviation (SD). Inter-group comparisons were evaluated via using Student’s t-test or t’ test. A P-value < 0.05 was defined as statistically significant. Results Synthesis and radiolabeling HER2 and RGD peptides were linked through a glutamate and polyethylene glycol linker, then HER2-RGD was labeled with 68Ga using DOTA as the chelating agent. The chemical structure of [68Ga]Ga-HER2-RGD is illustrated in Fig. 1A. Mass spectrometry analysis showed that the molecular ion [M + H]+ of the synthesized precursor was 8824.07, and the difference from the theoretical molecular weight of 8823.80 was within the allowable error range, demonstrating the correct structural synthesis of the two peptides. Quality control assessment via RP-HPLC confirmed that the labeled product possessed high quality. As shown in Fig. 1B, a distinct radioactive peak appeared at 17.06 min. The radiochemical purity was determined to be 97.61% ± 0.20% (n = 3). In vitro cell study Human breast cancer cell lines MDA-MB-435 S, MDA-MB-231, and MCF-7 were selected for the in vitro experiments. Flow cytometry was first conducted to assess the expression levels of HER2 and integrin αvβ3 in the three cell lines. As indicated in Fig. 2A, MDA-MB-435 S cells demonstrated high expression of both receptors, whereas MDA-MB-231 cells showed high HER2 but low αvβ3 level, and MCF-7 cells exhibited low levels of both. Furthermore, cell uptake assays (Fig. 2B) illustrated that the uptake of [68Ga]Ga-HER2-RGD by MDA-MB-435 S cells increased gradually over time, peaking at (13.2 ± 3.9)% at 90 min, with values of (9.2 ± 0.9)%, (10.8 ± 2.6)%, and (9.5 ± 0.2)% at 30, 60, 120 min, respectively. At 30, 60, 90, and 120 min, the cellular uptake values of the radiolabeled peptide in MDA-MB-231 cells were (7.4 ± 0.1)%, (7.5 ± 0.3)%, (7.7 ± 0.2)%, and (7.1 ± 0.2)%, respectively. The corresponding uptake values in MCF-7 cells were (5.8 ± 0.1)%, (5.9 ± 0.1)%, (5.9 ± 0.1)%, and (5.8 ± 0.1)%, respectively. Fig. 2(A) Flow cytometry confirms that MDA-MB-435 S cells expressed high levels of HER2 and integrin αvβ3, while MDA-MB-231 cells exhibited high HER2 levels but low αvβ3 expression, and MCF-7 cells showed low expression of both. (B,C) In vitro cell uptake and retention of [68Ga]Ga-HER2-RGD were higher in MDA-MB-435 S cells than in MDA-MB-231 cells. Furthermore, the uptake and retention in MDA-MB-231 cells were greater than those in MCF-7 cells at all time points. (D) Cellular uptake of [68Ga]Ga-HER2-RGD in MDA-MB-435 S cells following blockade with 10 µg unlabeled HER2-RGD. Data are presented as mean ± SD (n = 3), ***p < 0.001. (E) Competitive binding assays revealed that [68Ga]Ga-HER2-RGD exhibited high binding affinity, with an IC50 value of 12.9 nM (A) Flow cytometry confirms that MDA-MB-435 S cells expressed high levels of HER2 and integrin αvβ3, while MDA-MB-231 cells exhibited high HER2 levels but low αvβ3 expression, and MCF-7 cells showed low expression of both. (B,C) In vitro cell uptake and retention of [68Ga]Ga-HER2-RGD were higher in MDA-MB-435 S cells than in MDA-MB-231 cells. Furthermore, the uptake and retention in MDA-MB-231 cells were greater than those in MCF-7 cells at all time points. (D) Cellular uptake of [68Ga]Ga-HER2-RGD in MDA-MB-435 S cells following blockade with 10 µg unlabeled HER2-RGD. Data are presented as mean ± SD (n = 3), ***p < 0.001. (E) Competitive binding assays revealed that [68Ga]Ga-HER2-RGD exhibited high binding affinity, with an IC50 value of 12.9 nM A cell retention study showed that the retention rates of [68Ga]Ga-HER2-RGD in MDA-MB-435 S cells at 30, 60, 90, and 120 min were (74.6 ± 3.3)%, (72.7 ± 2.8)%, (68.9 ± 3.3)%, and (67.2 ± 4.2)%, respectively. At the different time points, the cellular retention values in MDA-MB-231 and MCF-7 cells were (62.7 ± 9.7)%, (56.5 ± 10.7)%, (55.9 ± 10.2)%, (48.0 ± 11.1)% and (43.9 ± 5.2)%, (39.1 ± 12.3)%, (38.5 ± 1.7)%, (37.1 ± 7.2)%, respectively (Fig. 2C). Cell blocking studies were performed to assess the in vitro specificity of [68Ga]Ga-HER2-RGD (Fig. 2D). The uptake of [68Ga]Ga-HER2-RGD by MDA-MB-435 S cells decreased significantly upon pretreatment with a 100-fold excess of the blocking amount, HER2-RGD (T/NT: Non-blocked: 13.2 ± 3.9 vs. Blocked: 2.7 ± 0.6, p < 0.001). Competitive binding assays revealed that [68Ga]Ga-HER2-RGD exhibited high binding affinity, with an IC50 value of 12.9 nM (Fig. 2E). Micro-PET/CT imaging and biodistribution analysis To evaluate the biodistribution and targeting capability of the heterodimeric tracer [68Ga]Ga-HER2-RGD in vivo, we performed microPET/CT scans in MDA-MB-435 S, MDA-MB-231, and MCF-7 tumor-bearing mice. PET scans were performed at 30, 60, 90, and 120 min p.i. As shown in the 3D MIP images in Fig. 3, [68Ga]Ga-HER2-RGD demonstrated features of rapid tumor accumulation, prolonged tumor retention, and superior tumor-to-background contrast. At 30 min p.i., the tumor was clearly discernible from the background, and the tumor contour remained distinct after 2 h. The biodistribution data presented in Fig. 4 indicated that [68Ga]Ga-HER2-RGD primarily accumulated in the tumor, kidneys, and bladder. Fig. 3Representative Micro-PET/CT images of [68Ga]Ga-HER2-RGD in MDA-MB-435 S, MDA-MB-231, and MCF-7 xenografts at different time points. Arrows indicate tumors Representative Micro-PET/CT images of [68Ga]Ga-HER2-RGD in MDA-MB-435 S, MDA-MB-231, and MCF-7 xenografts at different time points. Arrows indicate tumors Fig. 4Biodistribution of [68Ga]Ga-HER2-RGD in BALB/c nude mice bearing MDA-MB-435 S xenografts. (%ID/g: percentage of injected dose per gram of tissue) Biodistribution of [68Ga]Ga-HER2-RGD in BALB/c nude mice bearing MDA-MB-435 S xenografts. (%ID/g: percentage of injected dose per gram of tissue) As shown in Fig. 3, the tumor-to-non-tumor (T/NT) ratios in MDA-MB-435 S xenograft nude mice at different time points were 1.95 ± 0.32, 2.53 ± 0.56, 2.80 ± 0.92, and 2.73 ± 0.39, respectively. The uptake of the molecular probe in tumor tissues peaked at 90 min post-injection. At every time point, the T/NT ratios of MDA-MB-435 S xenografts were higher than those of MDA-MB-231 xenografts (1.54 ± 0.07, 1.63 ± 0.10, 1.80 ± 0.44, 1.57 ± 0.19, respectively). Furthermore, the T/NT ratios of MDA-MB-231 xenografts were higher than those of MCF-7 xenografts (0.94 ± 0.71, 0.99 ± 0.72, 0.80 ± 0.67, 0.97 ± 0.67, respectively). Blocking experiments were conducted in MDA-MB-435 S xenograft mice to confirm the in vivo specific uptake of [68Ga]Ga-HER2-RGD. The uptake of MDA-MB-435 S tumors was significantly decreased when co-injected with a blocking amount of nonradioactive HER2-RGD (T/NT: Non-blocked: 2.80 ± 0.92 vs. Blocked: 1.18 ± 0.71, p < 0.05) (Fig. 5A, B). Fig. 5Specificity of [68Ga]Ga-HER2-RGD uptake in BALB/c nude mice bearing MDA-MB-435 S xenografts. Data are presented as %ID/g. To saturate HER2 and/or αvβ3 integrin, animals in the blocking group were intravenously injected with 200 µg of unlabeled HER2-RGD prior to the administration of the radiolabeled conjugate. Data are presented as mean ± SD (n = 3), *p < 0.05 Specificity of [68Ga]Ga-HER2-RGD uptake in BALB/c nude mice bearing MDA-MB-435 S xenografts. Data are presented as %ID/g. To saturate HER2 and/or αvβ3 integrin, animals in the blocking group were intravenously injected with 200 µg of unlabeled HER2-RGD prior to the administration of the radiolabeled conjugate. Data are presented as mean ± SD (n = 3), *p < 0.05 Discussion Previous studies have shown that [68Ga]Ga-labeled HER2 and RGD peptides demonstrate potential in imaging HER2-positive and αvβ3-expressing tumors [14–16]. However, these radiopeptides are limited by several shortcomings, including suboptimal binding affinity, brief tumor retention times, and low tumor accumulation. Given that many tumors overexpress various receptors and exhibit intrinsic heterogeneity, probes capable of recognizing multiple targets may exhibit superior targeting affinity and efficiency relative to their single-receptor tracers. Therefore, a single bivalent tracer capable of targeting both markers constitutes a promising strategy to expand the target population. In this study, a dual-target heterodimer, DOTA-3PEG4-HER2-RGD, was successfully prepared and labeled with 68Ga, demonstrating high radiochemical yield and purity. As far as we know, this research represents the first application of a HER2-RGD heterodimeric probe for the diagnosis of solid tumors and to preliminarily assess its potential in breast cancer. In this study, three human breast cancer cell lines with distinct receptor expression profiles were selected to validate the targeting specificity of the probe. The cellular uptake assays demonstrated that [68Ga]Ga-HER2-RGD exhibited the highest uptake in MDA-MB-435 S cells (high HER2 and integrin αvβ3), followed by MDA-MB-231 (high HER2 and low integrin αvβ3), while negligible uptake was observed in MCF-7 cells (low HER2 and integrin αvβ3). This trend indicates a positive correlation between tracer uptake and receptor expression levels. Furthermore, cellular retention studies revealed that the tracer was retained more effectively in MDA-MB-435 S cells relative to the other lines, demonstrating specific binding affinity for HER2 and/or integrin αvβ3. This specificity was further confirmed by blocking experiments, in which excess unlabeled HER2-RGD significantly inhibited radiopeptide uptake in MDA-MB-435 S cells. Micro-PET/CT imaging demonstrated rapid accumulation of [68Ga]Ga-HER2-RGD in the tumors of nude mice. The T/NT ratio increased over time, peaking at 90 min post-injection. Notably, in MDA-MB-435 S xenografts, the tumors displayed clear delineation and exceptional contrast. This phenomenon is likely attributable to a “binding retention effect” resulting from the increased number of binding sites offered by the dual-targeting molecule. Consistent with the in vitro findings, the T/NT ratios across the three xenograft models followed the order: MDA-MB-435 S > MDA-MB-231 > MCF-7, further confirming a positive correlation between tracer uptake and receptor expression levels and demonstrating its capability to detect the expression levels of both receptors to a certain extent. The obvious decrease in the tumor accumulation of [68Ga]Ga-HER2-RGD after administering blocking amount of HER2-RGD demonstrated the specificity of the radiopeptide. [68Ga]Ga-HER2-RGD exhibited high binding affinity, with an IC50 value of 12.9 nM. The decline in tumor uptake observed at 120 min is likely attributable to the dissociation of the radiopeptide from the target receptors and the simultaneous washout of the unbound or metabolized tracer via the renal pathway. Tumor cell lines with varying HER2 and integrin αvβ3 expression were validated using the synthesized heterodimeric radiopeptide, which successfully distinguished receptor levels. Spatial heterogeneity in solid tumors often causes false negatives with monospecific probes. Our data show that the heterodimeric radioligand maintains high sensitivity via dual-target complementation. This makes it a promising tool for non-invasive phenotyping and tracking receptor expression. Intense renal and bladder uptake was observed in tumor-bearing nude mice, suggesting that the tracer is predominantly excreted via the urinary system—a metabolic feature typical of peptide drugs that facilitates reduced background interference [17]. Tracer accumulation in kidneys was intense, which may be a drawback when considering the use of 177Lu- or 90Y-labeled HER2-RGD for peptide receptor radionuclide therapy (PRRT). Further optimization of the compound is warranted, such as balancing hydrophilicity and lipophilicity, appropriately prolonging circulation time to minimize washout, and employing an enzymolysis clearance strategy to facilitate renal elimination. Additionally, Micro-PET/CT imaging revealed significant accumulation in the liver and intestines, indicating a hepatobiliary excretion component. This observation is consistent with reports on various RGD-based tracers; for instance, [111In]In-DOTA-2P-RGD4 exhibits simultaneous renal and hepatobiliary excretion within the observation period [18]. Furthermore, studies on PEGylation have demonstrated that mPEG conjugates significantly reduce renal uptake while moderately increasing hepatic accumulation [19]. In contrast, standalone HER2-targeting PEG4 monomeric peptides (e.g., [177Lu]Lu-DOTA-PEG4-A9) primarily demonstrate renal excretion and rapid washout from non-target organs [20]. Therefore, the high hepatic and intestinal uptake of [68Ga]Ga-DOTA-3PEG4-HER2-RGD observed in this study likely stems from the hepatobiliary clearance synergistically induced by the RGD motif and the PEG4 modification, whereas the HER2-targeting moiety remains inclined toward renal excretion. Future experimental studies are planned to characterize the time-activity curves of hepatic uptake or to investigate shorter PEG linkers to validate this hypothesis. This study has several limitations that should be acknowledged. Firstly, this heterodimeric tracer cannot differentiate whether the tumor uptake in animal models is driven by HER2 or integrin αvβ3. Secondly, blocking studies with monospecific competitors were not conducted. Therefore, future studies are warranted to incorporate target-specific blocking experiments and comparative immunohistochemical analyses to fully delineate the individual contribution of each target to the overall tumor uptake. Conclusion Herein, we describe the design, synthesis, and 68Ga labeling of a novel heterodimeric ligand, HER2-RGD, engineered to target both HER2 and integrin αvβ3 receptors. Moreover, the radiopeptide allows for a semi-quantitative assessment of HER2 and/or integrin αvβ3 expression levels to some extent, marking it as a strong candidate for clinical translation.